AU2001246934A1 - Agonist antibodies - Google Patents

Agonist antibodies

Info

Publication number
AU2001246934A1
AU2001246934A1 AU2001246934A AU4693401A AU2001246934A1 AU 2001246934 A1 AU2001246934 A1 AU 2001246934A1 AU 2001246934 A AU2001246934 A AU 2001246934A AU 4693401 A AU4693401 A AU 4693401A AU 2001246934 A1 AU2001246934 A1 AU 2001246934A1
Authority
AU
Australia
Prior art keywords
agonist antibodies
agonist
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001246934A
Inventor
Naoshi Fukushima
Yasufumi Kikuchi
Masayoshi Oh-Eda
Toshihiko Ohtomo
Masayuki Tsuchiya
Shinsuke Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2001/001912 external-priority patent/WO2001066737A1/en
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001246934A1 publication Critical patent/AU2001246934A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2001246934A 2000-04-17 2001-04-17 Agonist antibodies Abandoned AU2001246934A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2000-115246 2000-04-17
JP2000115246 2000-04-17
JP2000321822 2000-10-20
JP2000321821 2000-10-20
JP2000-321822 2000-10-20
JP2000-321821 2000-10-20
WOJP01/01912 2001-03-12
PCT/JP2001/001912 WO2001066737A1 (en) 2000-03-10 2001-03-12 Polypeptide inducing apoptosis
PCT/JP2001/003288 WO2001079494A1 (en) 2000-04-17 2001-04-17 Agonist antibodies

Publications (1)

Publication Number Publication Date
AU2001246934A1 true AU2001246934A1 (en) 2001-10-30

Family

ID=27455291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001246934A Abandoned AU2001246934A1 (en) 2000-04-17 2001-04-17 Agonist antibodies

Country Status (2)

Country Link
AU (1) AU2001246934A1 (en)
WO (1) WO2001079494A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
KR20030055274A (en) 2000-10-20 2003-07-02 츄가이 세이야꾸 가부시키가이샤 Degraded tpo agonist antibody
JP4518941B2 (en) 2002-04-26 2010-08-04 中外製薬株式会社 Agonist antibody screening method
JP2004279086A (en) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc Radiation image conversion panel and method for manufacturing it
JP4794301B2 (en) 2003-06-11 2011-10-19 中外製薬株式会社 Antibody production method
JPWO2005056602A1 (en) * 2003-12-12 2008-03-06 中外製薬株式会社 Screening method for modified antibodies having agonist activity
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
TW200718780A (en) * 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU740225B2 (en) * 1997-09-11 2001-11-01 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
WO2000053634A1 (en) * 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis

Also Published As

Publication number Publication date
WO2001079494A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2002210918A1 (en) Degraded agonist antibody
AU1091802A (en) Degraded agonist antibody
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002210917A1 (en) Degraded TPO agonist antibody
AU1290001A (en) Antibodies
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
AU2001240819A1 (en) Proteomics database
AU1091702A (en) Degraded tpo agonist antibody
AU2001234125A1 (en) Antibody library
AU4935000A (en) Antibodies
AU2002365649A1 (en) Anti-dota antibody
AU2001246934A1 (en) Agonist antibodies
AU2001239773A1 (en) Baroplastic materials
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001254731A1 (en) Substituted phenyluracils
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001220281A1 (en) Rollerboard for road-skiing
AU2002239291A1 (en) G protein coupled receptors
AU2001266176A1 (en) Methods
AU8293201A (en) Applause device
AU2002221132A1 (en) Novel antibody
AU2001223882A1 (en) Receptor
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001244863A1 (en) Apoptin-associating protein
AU2001250536A1 (en) Methods